Wed, Jul 23, 2014, 5:12 AM EDT - U.S. Markets open in 4 hrs 18 mins


% | $
Click the to save as a favorite.

Geron Corporation (GERN) Message Board

  • franshei franshei Dec 6, 2012 12:05 PM Flag

    GRN1005 is now ANG1005

    This prodrug is now back to AngioChem (see website). I think GERN will not talk too much about GRN1005 from here on and the GERN website will focus in imetetstat from here on.

    GERN's preclinical success and early clinical success in ET and short-chain tolemerase-related solid tumors mean a lot. Incyte's success is built on their drugs in ET. If imetetstat is a better molecule in various ET related indications, I think Incyte may come in to buy out GERN. Paul Friedman came from DuPont/Merck/Bristol (where I spent a total of 10 years there) and I think I may know what the company may do.

    I think we should not take GERN too lightly with its new strategy. We should know more over this weekend, during ASH.

2.59-0.13(-4.78%)Jul 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.